NCT03333616 2026-01-21
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
University of California, San Francisco
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AHS Cancer Control Alberta